Cost-Effectiveness Analysis of Continuous-Flow Left Ventricular Assist Devices as Destination Therapy
Authors:
- Robin R. BosticRBRobin R. Bostic
- Kuo B. TongKTKuo B. Tong
- Rob AdamsonRARob Adamson
- Mark RussoMRMark Russo
- Mark S. SlaughterMSMark S. Slaughter
- 1 January 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 5 (1) , 10-16
Abstract
Background—: Continuous-flow left ventricular assist devices (LVADs) have become the dominant devices for mechanical circulatory support, but their cost-effectiveness is undetermined. This study assessed the cost-effectiveness of continuous-flow devices for destination therapy versus optimal medical management in advanced heart failure and compared the results with previous estimates for pulsatile devices. Methods and Results—: A Markov model was developed to assess cost-effectiveness. Survival, hospitalization rates, quality of life, and cost data were obtained for advanced heart failure patients treated medically or with a continuous-flow LVAD. Rates of clinical outcomes for all patients were obtained from clinical trial databases. Medicare prospective payments were used to estimate the cost of heart failure admissions. The cost of LVAD implantation was obtained prospectively from hospital claims within a clinical trial. Compared with medically managed patients, continuous-flow LVAD patients had higher 5-year costs ($360 407 versus $62 856), quality-adjusted life years (1.87 versus 0.37), and life years (2.42 versus 0.64). The incremental cost-effectiveness ratio of the continuous-flow device was $198 184 per quality-adjusted life year and $167 208 per life year. This equates to a 75% reduction in incremental cost-effectiveness ratio compared with the $802 700 per quality-adjusted life year for the pulsatile-flow device. The results were most sensitive to the cost of device implantation, long-term survival, cost per rehospitalization, and utility associated with patients' functional status. Conclusions—: The cost-effectiveness associated with continuous-flow LVADs for destination therapy has improved significantly relative to the pulsatile flow devices. This change is explained by significant improvements in survival and functional status and reduction in implantation costs.Keywords
This publication has 21 references indexed in Scilit:
- How to assess the value of medicines?Frontiers in Pharmacology, 2010
- Renal and Hepatic Function Improve in Advanced Heart Failure Patients During Continuous-Flow Support With the HeartMate II Left Ventricular Assist DeviceCirculation, 2009
- Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist DeviceNew England Journal of Medicine, 2009
- Rise of the Machines — Left Ventricular Assist Devices as Permanent Therapy for Advanced Heart FailureNew England Journal of Medicine, 2009
- Rehospitalizations among Patients in the Medicare Fee-for-Service ProgramNew England Journal of Medicine, 2009
- Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for people with end-stage heart failure: A systematic review and economic evaluationInternational Journal of Technology Assessment in Health Care, 2007
- Hospital Costs for Left Ventricular Assist Devices for Destination Therapy: Lower Costs for Implantation in the Post-REMATCH EraThe Journal of Heart and Lung Transplantation, 2006
- Left Ventricular Assist Devices as Permanent Heart Failure TherapyAnnals of Surgery, 2003
- Long-Term Use of a Left Ventricular Assist Device for End-Stage Heart FailureNew England Journal of Medicine, 2001
- Evolving Costs of Long-Term Left Ventricular Assist Device ImplantationThe Annals of Thoracic Surgery, 1997